Sugi Predict

Sugi Predict / Compounds / SCHEMBL2881990

SCHEMBL2881990

SCHEMBL2881990

O=C1NC(=O)C(=Cc2ccc3ncsc3c2)S1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 14/20 0.79
▸ DYRK2 Q92630 13/20 0.79
▸ DYRK1B Q9Y463 13/20 0.79
▸ CLK1 P49759 13/20 0.79
▸ CLK4 Q9HAZ1 10/20 0.79
▸ CSNK2A2 P19784 4/20 0.79
▸ CSNK2B P67870 3/20 0.79
▸ CSNK2A1 P68400 3/20 0.79
▸ PIK3CD O00329 3/20 0.79
▸ PIK3CA P42336 3/20 0.79
▸ PIK3CG P48736 3/20 0.79
▸ PRKCB P05771 1/20 0.79
▸ HASPIN Q8TF76 1/20 0.79
▸ CISD1 Q9NZ45 3/20 0.64
▸ PIK3CB P42338 2/20 0.64
▸ MTOR P42345 2/20 0.64
▸ NPC1 O15118 1/20 0.64
▸ MAOB P27338 1/20 0.64
▸ RAB9A P51151 1/20 0.64
▸ GSK3B P49841 10/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881987 1.00 DYRK1A (0.79) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL2787896 0.79 CLK1 (0.73) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL2787898 0.79 CLK1 (0.73) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL13196791 0.79 CLK1 (0.73) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL29358448 0.78 CISD1 (1.00) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL668616 0.78 CISD1 (1.00) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL16416224 0.78 CISD1 (1.00) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL668617 0.78 CISD1 (1.00) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL2787533 0.78 DYRK3 (0.69) DYRK1ADYRK2DYRK1BCLK1CLK4
SCHEMBL13196777 0.78 DYRK3 (0.69) DYRK1ADYRK2DYRK1BCLK1CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US claimed
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 — — US claimed
EP-1807075-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA Applied Research Systems ARS Holding N.V. (AN) 2007-07-18 — — EP claimed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 — — US claimed
WO-2006040318-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-04-20 — — WO claimed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 — — US claimed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 — — EP claimed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 — — WO claimed
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US disclosed
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-12-10 — — US disclosed
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2008-12-11 — — US disclosed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 — — US disclosed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 — — US disclosed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 — — EP disclosed
EP-1531813-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY Applied Research Systems ARS Holding N.V. (AN) 2005-05-25 — — EP disclosed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 — — WO disclosed
WO-2004006916-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES ZAP70, BRCA1, ZYX DYRK1A 3161/4885DYRK2 2734/4885DYRK1B 2749/4885
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia PDPK1, PRKD3, PRKD1 DYRK1A 362/4885DYRK2 446/4885DYRK1B 389/4885
US-20050222225-A1 Use of compounds for increasing spermatozoa motility CATSPER1, PI4KB, MAN2B2 DYRK1A 4508/4885DYRK2 4464/4885DYRK1B 4430/4885
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis PDPK1, PIK3R4, MAP3K3 DYRK1A 1259/4885DYRK2 1446/4885DYRK1B 1267/4885
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives BRCA1, ZAP70, F13B DYRK1A 3215/4885DYRK2 2830/4885DYRK1B 2890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.